01 / ATLAS
What it is
TB-500 is associated with the LKKTETQ fragment of thymosin beta-4. The name and exact chemical identity matter: the fragment and the full peptide are not interchangeable. [1]
02 / ATLAS
How it works
Interest in tissue repair comes from research on thymosin beta-4 and its interaction with actin, part of the cellular skeleton. The full peptide’s mechanism does not demonstrate the same clinical effect for TB-500. [2]
03 / ATLAS
What research shows
Data on full-length thymosin beta-4 must be read separately from data on the fragment. FDA documentation for TB-500 does not provide sufficient clinical evidence to establish wound healing in humans. [2]
04 / ATLAS
Study data
The 2026 FDA assessment examines TB-500 separately. We do not use studies of other thymosin beta-4 forms as a source of doses or efficacy percentages for the fragment. [2]
05 / ATLAS
Safety and observed adverse reactions
The FDA notes a lack of identified human exposure data for the fragment and potential impurity and immune-response risks. [1]
06 / ATLAS
Research status
The fragment’s clinical safety and efficacy remain insufficiently characterized in the cited sources. This entry does not present a therapeutic protocol.
07 / REFERENCES
Studies and sources
- FDA · Thymosin beta-4 fragment (TB-500) ↗Official assessment · identity and safety
- FDA · Peptide evaluation documentation (2026) ↗Official document · PDF